Transcript of Earnings Call on Unaudited Standalone and Consolidated Financial Resullts for the quarter ended June 30, 2026.

gaudium Delivering Motherhood Dreams August 19, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Exchange Plaza, C-1, Block G, Bandra Kurla Towers, Dalal Street, Fort, Complex, Bandra (E), Mumbai 400051, Mumbai -400001, Maharashtra 'Maharashtra Scrip Code 544709 Symbol GAUDIUMIVF ISIN: INE0P8B01020 ISIN: INE0P8B01020 Subject: Transcript of Earnings Call on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 Dear Sir/Ma'am Pursuant to Regulation 30 and Regulation 46 read with Part A of Schedule III of the SEВI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the transcript of the Earnings Conference Call held on Friday, August 14, 2026, for the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The said transcript is also available on website of the Company at: https://www.gaudiumivfcentre.com/investors We request you to kindly take the same on record. Thanking you, Yours faithfully. For and on behalf of Gaudium IVF and Women Health Limited (Formerly known as Gaudium IVF and Women Health Private Limited) Naveen Kumar Company Secretary and Compliance Officer Membership No: A69788 Encl: a/a Gaudium IVF and Women Health Limited (Formerly known as Gaudium IVF and Women Health Pvt. Ltd.) Registered Office : B1/51, Janakpuri, New Delhi- 110058 | Ph: 011-4885 8585 CIN: L85100DL2015PLC278296 Email: info@gaudiumivfcentre.com Website : www.gaudiumivfcentre.com “Gaudium IVF and Women Health Limited Q1 FY27 Earnings Conference Call” August 14, 2026 MANAGEMENT: DR. MANIKA KHANNA – CHAIRPERSON AND MANAGING DIRECTOR – GAUDIUM IVF AND WOMEN HEALTH LIMITED MR. RAKESH KUMAR SHARMA – CHIEF FINANCIAL OFFICER – GAUDIUM IVF AND WOMEN HEALTH LIMITED ADFACTORS PR – INVESTOR RELATIONS PARTNERS – GAUDIUM IVF AND WOMEN HEALTH LIMITED Gaudium IVF and Women Health Limited August 14, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Gaudium IVF and Women Health Limited Q1 FY27 Earnings Conference Call. This conference call may contain forward- looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as on the date of this call. These statements do not guarantee the future performance of the company and may involve risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF and Women Health Limited. Thank you, and over to you, ma'am. Dr. Manika Khanna: Thank you so much for the kind introduction. Good afternoon everyone. I'm Dr. Manika Khanna this side and I would like to welcome all of you on behalf of Gaudium IVF and Women Health Limited to the Q1 FY27 earnings conference call. I am happy this is our first full quarter as a publicly listed company, and I'm pleased to share that it has been a quarter of steady, disciplined execution, one that reflects both the strength of our clinical foundation and the momentum of our expansion roadmap. With me on the call today is Mr. Rakesh Sharma, our Chief Financial Officer, who will take you through the financials. We are also supported by our investor relation partners Adfactors PR. Now before I dive into the quarter, I'll just give you a brief industry backdrop. Let's reiterate the context in which we are operating. The Indian fertility market remains one of the most structurally attractive healthcare segments in the country. Large, deeply underpenetrated, and now in the early stages of a once-in-a-generation institutionalization aided by the ART and Surrogacy Act. So as we all know that this Act was introduced in 2022 and is in various phases of implementation across the country. We as one of the leaders are quite sure that when full implementation is there, there will be more and more consolidation in the industry and the organized player share is going to rise. Nearly 27.5 million couples in India are affected by infertility and yet around 3 lakhs IVF cycles are performed annually. So imagine what a huge amount of untapped market is lying there. Add to this delayed parenthood, rising awareness, a steadily reducing stigma, and a very meaningful medical tourism opportunity where the cost of an IVF cycle in India is roughly 1/5th of what it is in the United States Page 2 of 12 Gaudium IVF and Women Health Limited August 14, 2026 Dr. Manika Khanna: Gaudium is well placed to be one of the principal beneficiaries of this shift and you will realize this more as I speak. As far as the Q1 FY27 performance, coming to our quarterly performance, our revenue for Q1 FY27 grew by 9.1% year-on-year to ₹19.4 crores. Reported EBITDA and PAT for the quarter stood at ₹2.4 crores and ₹1.8 crores respectively, moderating on a year-on-year basis. This moderation is a direct reflection of the investments we have consciously made ahead of our 27 hub roll out, a trade-off I will speak about shortly. Rakesh will walk you through the detailed numbers as well shortly. IVF treatment continues to anchor the business, supported by our clinical pregnancy success rate of over 58%, which I am very happy to share has grown to 62% in the first attempt. And I will just enlighten you on the reason where this growth is coming from. This is at par with global standards and comparable to the best players in the world. Our cumulative pregnancy rate stands at as high as 85%. These outcomes are a direct reflection of our clinician-led DNA, our SOP-driven model refined over 17 years of hard work, and the depth of clinical talent we have built. I'll just throw some light on the AI led embryology that we introduced on the 1st of April, and since then we have steadily integrated it across our centres. I am talking about SiD and ERICA. These are two AI tools which have been brought for the first time outside of the US inside the human IVF lab. The early clinical benefits of our AI embryology tools which we formally integrated in partnership with IVF 2.0 are beginning to reflect in embryo selection consistency and in better sperm selection with the use of both these software. As I mentioned in the last call, in the very early results we are seeing close to an approximately 8% improvement in first attempt outcomes with these tools in the patients where this has been used. That trend continues to hold as we scale usage across our network, and we remain the first IVF chain in India to have formally integrated AI-led embryology, SiD and ERICA, into routine clinical practice. Regarding our pharmacy and hospital business, beyond our core IVF treatment business, our in-house pharmacy operations and hospital services continue to complement the platform. The pharmacy vertical supports our IVF patients through a curated, quality-assured supply of fertility medications and consumables, while our hospital operations extend into allied women health services including gynaecology, obstetrics, and minimally invasive procedures which go, you know, kind of hand-in-hand with IVF. While these segments carry structurally lower margins compared to our core IVF business, they play an important role in strengthening the patient journey end-to-end, deepening the wallet share per patient, and reinforcing Gaudium's positioning as a comprehensive women's health platform rather than a pure IVF chain. I will now run you most importantly through the strategic milestones that we achieved during the quarter. The quarter saw developments on the expansion side that I believe are particularly Page 3 of 12 Gaudium IVF and Women Health Limited Augu [Showing first 8,000 characters — download PDF for full document]